UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the quarterly period ended March 31, 2024
or
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
For the transition period from ________ to _________
Commission File Number: 001-39486
(Exact name of registrant as specified in its charter)
|
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
||
|
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
(866 ) 688-7374
(Registrant’s telephone number, including area code)
Not applicable
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
The
|
||
|
|
|
The
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes
☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an
emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
|
|
☒
|
Smaller reporting company
|
|
|
Emerging growth company
|
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 3, 2024, the registrant had 121,878,989
shares of Class A common stock outstanding and 19,937,500 shares of Class B common stock outstanding.
QUANTUM-SI INCORPORATED
FORM 10-Q
For the quarterly period ended March 31, 2024
|
Page
|
||
| 2 |
||
| |
||
|
Part I
|
3 |
|
|
Item 1.
|
3
|
|
| 3 |
||
| 4 |
||
| 5 |
||
| 6 |
||
| 7 |
||
|
Item 2.
|
21 |
|
|
Item 3.
|
26
|
|
|
Item 4.
|
26 |
|
|
Part II
|
27 |
|
|
Item 1.
|
27
|
|
|
Item 1A.
|
27 |
|
|
Item 2.
|
27 |
|
|
Item 3.
|
27 |
|
|
Item 4.
|
27 |
|
|
|
||
|
Item 5.
|
27 |
|
|
Item 6.
|
28 |
|
| 29 |
||
In this Quarterly Report on Form 10-Q, the terms “we”, “us”, “our”, the “Company” or “Quantum-Si” mean Quantum-Si Incorporated and our
subsidiaries. Quantum-Si Incorporated was incorporated in Delaware on June 10, 2020.
This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933,
as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that relate to future events, our future operations or financial performance, or our plans, strategies and prospects.
These statements are based on the beliefs and assumptions of our management team. Although we believe that our plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, we cannot assure that
we will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning
possible or assumed future actions, business strategies, events or performance, are forward-looking statements. The actual results may differ from its expectations, estimates, and projections and, consequently, you should not rely on these
forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,”
and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, our expectations with respect to future
performance and development and commercialization of products and services. The forward-looking statements are based on projections prepared by, and are the responsibility of, management and involve significant risks and uncertainties that could
cause the actual results to differ materially from those discussed in the forward-looking statements. Most of these factors are outside our control and are difficult to predict. Forward-looking statements contained in this Quarterly Report on
Form 10-Q include, but are not limited to, statements about:
| • |
the impact of pandemics or epidemics on our business;
|
| • |
the inability to maintain the listing of our Class A common stock on The Nasdaq Stock Market LLC;
|
| • |
changes in applicable laws or regulations;
|
| • |
our ability to raise financing in the future;
|
| • |
the success, cost and timing of our product development and commercialization activities;
|
| • |
the commercialization and adoption of our existing products, including the Platinum® protein sequencing instrument, and the success of
any product we may offer in the future;
|
| • |
our ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved product;
|
| • |
our ability to identify, in-license or acquire additional technology;
|
| • |
our ability to maintain our existing lease, license, manufacture and supply agreements;
|
| • |
our ability to compete with other companies currently marketing or engaged in the development or commercialization of products and services that
serve customers engaged in proteomic analysis, many of which have greater financial and marketing resources than us;
|
| • |
the size and growth potential of the markets for our products and services, and its ability to serve those markets once commercialized, either alone
or in partnership with others;
|
| • |
our estimates regarding future expenses, future revenue, capital requirements and needs for additional financing; and
|
| • |
our financial performance.
|
These forward-looking statements are based on information available as of the date of this report, and current expectations, forecasts
and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results, performance or achievements to differ materially from those indicated or implied by forward-looking statements such as
those described in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, in Part II, Item 1A of this Quarterly Reports on Form 10-Q, and in other filings that we make with the Securities
and Exchange Commission. The risks described under the heading “Risk Factors” are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can we assess the impact of all such risk
factors on our business or the extent to which any factor or combination of factors may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of
performance. You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the
foregoing cautionary statements. We undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
QUANTUM-SI INCORPORATED
(in thousands, except share and par value amounts)
|
(unaudited)
March 31, |
December 31,
2023 |
|||||||
|
Assets
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
|
$
|
|
||||
|
Marketable securities
|
||||||||
|
Accounts receivable, net of allowance of $
|
||||||||
|
Inventory, net
|
||||||||
|
Prepaid expenses and other current assets
|
|
|
||||||
|
Total current assets
|
|
|
||||||
|
Property and equipment, net
|
|
|
||||||
| Internally developed software |
||||||||
|
Operating lease right-of-use assets
|
|
|
||||||
| Other assets | ||||||||
|
Total assets
|
$
|
|
$
|
|
||||
|
Liabilities and stockholders’ equity
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable
|
$
|
|
$
|
|
||||
|
Accrued payroll and payroll-related costs
|
||||||||
|
Accrued contracted services
|
||||||||
|
Accrued expenses and other current liabilities
|
|
|
||||||
|
Current portion of operating lease liabilities
|
||||||||
|
Total current liabilities
|
|
|
||||||
|
Warrant liabilities
|
|
|
||||||
|
Operating lease liabilities
|
||||||||
|
Other long-term liabilities
|
|
|
||||||
|
Total liabilities
|
|
|
||||||
|
Commitments and contingencies (Note 15)
|
||||||||
|
Stockholders’ equity
|
||||||||
|
Class A Common stock, $
|
|
|
||||||
|
Class B Common stock, $
|
|
|
||||||
|
Additional paid-in capital
|
|
|
||||||
| Accumulated other comprehensive loss |
( |
) | ||||||
|
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
|
Total stockholders’ equity
|
|
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
||||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
QUANTUM-SI INCORPORATED
(in thousands, except per share amounts)
(unaudited)
|
Three months ended March 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
Revenue:
|
||||||||
|
Product
|
$ | $ | ||||||
|
Service
|
||||||||
|
Total revenue
|
||||||||
|
Cost of revenue
|
||||||||
| Gross profit |
||||||||
|
Operating expenses:
|
||||||||
|
Research and development
|
|
|
||||||
|
Selling, general and administrative
|
|
|
||||||
|
Total operating expenses
|
|
|
||||||
|
Loss from operations
|
(
|
)
|
(
|
)
|
||||
|
Dividend and interest income
|
||||||||
| Gain on marketable securities, net |
||||||||
|
Change in fair value of warrant liabilities
|
|
|
||||||
|
Other (expense) income, net
|
(
|
)
|
|
|||||
|
Loss before provision for income taxes
|
(
|
)
|
(
|
)
|
||||
|
Provision for income taxes
|
|
|
||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Net loss per common share attributable to common stockholders, basic and diluted
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
|
|
|
||||||
| Other comprehensive loss: |
||||||||
|
Net unrealized loss on marketable securities, net of tax
|
$ | ( |
) | $ | ||||
|
Foreign currency translation adjustment
|
( |
) | ||||||
|
Total other comprehensive loss, net of tax
|
( |
) | ||||||
| Comprehensive loss |
$ | ( |
) | $ | ( |
) | ||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
QUANTUM-SI INCORPORATED
(in thousands, except share amounts)
(unaudited)
|
Class A common stock
|
Class B common stock
|
Additional
paid-in
|
Accumulated |
Total
stockholders’
|
||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
capital
|
deficit
|
equity
|
||||||||||||||||||||||
|
Balance - December 31, 2022
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||||||||
|
Common stock issued upon vesting of restricted stock units
|
|
|
|
|
|
|
|
|||||||||||||||||||||
|
Stock-based compensation
|
-
|
|
-
|
|
|
|
|
|||||||||||||||||||||
|
Net loss
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||
|
Balance - March 31, 2023
|
|
$
|
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||||||||||
|
Class A common stock
|
Class B common stock
|
Additional
paid-in
|
Accumulated
other
compehensive
|
Accumulated |
Total
stockholders’
|
|||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
capital
|
loss |
deficit
|
equity
|
|||||||||||||||||||||||||
|
Balance - December 31, 2023
|
|
$
|
|
|
$
|
|
$
|
|
$ |
$
|
(
|
)
|
$
|
|
||||||||||||||||||
|
Common stock issued upon vesting of restricted stock units
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
|
Stock-based compensation
|
-
|
|
-
|
|
|
|
|
|||||||||||||||||||||||||
|
Net unrealized loss on marketable securities, net of tax
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Refund of issuance costs from 2021 Business Combination
|
- | - | ||||||||||||||||||||||||||||||
| Foreign currency translation |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Net loss
|
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||
|
Balance - March 31, 2024
|
|
$
|
|
|
$
|
|
$
|
|
$ |
( |
) |
$
|
(
|
)
|
$
|
|
||||||||||||||||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
QUANTUM-SI INCORPORATED
(in thousands)
(unaudited)
|
Three Months Ended March 31,
|
||||||||
|
2024
|
2023
|
|||||||
|
Cash flows from operating activities:
|
||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Depreciation and amortization
|
|
|
||||||
|
Non-cash lease expense
|
||||||||
|
(Gain) loss on marketable securities, net
|
( |
) | ||||||
|
(Accretion) amortization on marketable securities
|
( |
) | ||||||
|
(Gain) loss on disposal of fixed assets
|
||||||||
|
Change in fair value of warrant liabilities
|
(
|
)
|
(
|
)
|
||||
|
Change in fair value of contingent consideration
|
||||||||
|
Stock-based compensation
|
|
|
||||||
|
Other
|
||||||||
|
Changes in operating assets and liabilities:
|
||||||||
|
Accounts receivable, net
|
( |
) | ||||||
|
Inventory, net
|
( |
) | ( |
) | ||||
|
Prepaid expenses and other current assets
|
|
|
||||||
|
Accounts payable
|
(
|
)
|
(
|
)
|
||||
|
Accrued expenses and other current liabilities
|
(
|
)
|
(
|
)
|
||||
|
Operating lease liabilities
|
( |
) | ( |
) | ||||
| Other long-term liabilities | ||||||||
|
Net cash used in operating activities
|
|
(
|
)
|
|
(
|
)
|
||
|
Cash flows from investing activities:
|
||||||||
|
Purchases of property and equipment
|
(
|
)
|
(
|
)
|
||||
|
Internally developed software - capitalized costs
|
( |
) | ( |
) | ||||
| Purchases of marketable securities | ( |
) | ||||||
|
Sales of marketable securities
|
||||||||
|
Net cash (used in) provided by investing activities
|
|
(
|
)
|
|
|
|||
|
Cash flows from financing activities:
|
||||||||
|
Deferred offering costs
|
( |
) | ||||||
|
Refund of issuance costs from
2021 Business Combination
|
||||||||
|
Net cash used in financing activities
|
|
(
|
)
|
|
|
|||
| Effect of exchange rate changes on cash and cash equivalents | ( |
) | ||||||
|
Net decrease in cash and cash equivalents
|
(
|
)
|
(
|
)
|
||||
|
Cash and cash equivalents at beginning of period
|
|
|
||||||
|
Cash and cash equivalents at end of period
|
$
|
|
$
|
|
||||
| Supplemental disclosure of cash flow information: | ||||||||
|
Cash paid for income taxes
|
$ |
$ |
||||||
|
Supplemental disclosure of non-cash investing and financing activities:
|
||||||||
|
Property and equipment purchased but not paid
|
$
|
|
$
|
|
||||
|
Deferred offering costs payable
|
$ |
$ |
||||||
The accompanying notes are an integral part of these unaudited Condensed Consolidated Financial Statements.
QUANTUM-SI INCORPORATED
(Unaudited)
Note 1. Organization and Description of Business
Quantum-Si Incorporated (including its
subsidiaries, the “Company” or “Quantum-Si”) was incorporated in Delaware on June 10, 2020 as HighCape Capital Acquisition Corp. The Company’s legal name became Quantum-Si Incorporated following a business combination on June 10, 2021 between
the Company and Q-SI Operations Inc. (formerly Quantum-Si Incorporated), which was founded in 2013.
The Company is an innovative life sciences company with the mission of
transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set of proteins expressed within a cell. The Company has developed a proprietary universal single-molecule
detection platform that the Company is first applying to proteomics to enable Next-Generation Protein SequencingTM (“NGPS”), the ability to sequence
proteins in a massively parallel fashion (rather than sequentially, one at a time), and can be used for the study of nucleic acids. The Company’s platform is currently comprised of the Platinum® NGPS instrument, the Platinum Analysis Software service, reagent kits and semiconductor chips for use with its instruments.
Note 2. Summary of Significant Accounting Policies
Basis of Presentation and Principles of Consolidation
The accompanying Condensed Consolidated Financial Statements include the accounts of the Company and have been prepared in
accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”). All intercompany
transactions are eliminated.
These Condensed Consolidated Financial Statements should be read in conjunction with the audited Consolidated Financial
Statements and the notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Condensed Consolidated Balance Sheets as of December 31, 2023 included herein was derived from the audited Consolidated
Financial Statements as of that date, but does not include all disclosures, including certain notes required by U.S. GAAP, on an annual reporting basis.
In the opinion of management, the accompanying Condensed Consolidated Financial Statements reflect all normal recurring
adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods. The results for the three months ended March 31, 2024 are not necessarily indicative of the results to be expected for any subsequent quarter, the year ending December 31, 2024, or any other period.
There have been no material changes to the
Company’s significant accounting policies as described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.
Global Developments
Throughout 2023, various central banks around the world, including the
Federal Reserve in the United States, raised interest rates. While these rate increases have not had a significant adverse impact on the Company to date, the impact of such rate increases on the overall financial markets and the economy may
adversely impact the Company in the future. In addition, the global economy has experienced, and is continuing to experience, high levels of inflation and global supply chain disruptions. The Company continues to monitor these supply chain,
inflation and interest rate factors, as well as the uncertainty resulting from the overall economic environment.
Although the Company does not expect to be significantly impacted by the
conflicts in Ukraine or Israel and Gaza, the Company has experienced some constraints in product and material availability and increasing costs required to obtain some materials and supplies as a result of these conflicts on the global
economy. To date, the Company’s business has not been materially impacted by the conflicts, however, as the conflicts continue or worsen, it may impact the Company’s business, financial condition, results of operations and cash flows.
Concentration of Business Risk
Financial instruments that potentially subject the Company to
concentration of credit risk consist principally of cash and cash equivalents and marketable securities. As of March 31, 2024, the Company’s marketable securities consist of mutual funds, U.S. Treasury securities and commercial paper. The
Company also maintains balances in certain operating accounts above federally insured limits and, as a result, the Company is exposed to credit risk in the event of default by the financial institutions to the extent account balances exceed
the amount insured by the Federal Deposit Insurance Corporation.
The Company sources certain key materials and components
utilized in the Company’s products from single or limited suppliers. Historically, the Company has not experienced significant issues sourcing these materials and components. However, if these suppliers were not able to supply the requested
amount of materials or components, it could take a considerable length of time to obtain alternative sources, which could affect the Company’s development efforts and commercial operations.
Segment Reporting
The Company’s Chief Operating Decision Maker, its Chief Executive Officer, reviews the Company’s financial information on a consolidated
basis for purposes of allocating resources and evaluating its financial performance. Accordingly, the Company has determined that it operates as a single reportable segment.
Reclassifications
Certain prior year amounts have been reclassified for consistency with the current year’s presentation.
Use of Estimates
The preparation of the Condensed Consolidated Financial Statements in conformity
with U.S. GAAP requires the Company to make estimates and assumptions about future events that affect the amounts recorded in its Condensed Consolidated Financial Statements and accompanying notes. Future events and their effects cannot be
determined with certainty. On an ongoing basis, management evaluates these estimates and assumptions. Significant estimates and assumptions include:
| ● |
valuation allowances with respect to deferred tax assets;
|
| ● |
inventory valuation;
|
| ● |
valuation of excess and obsolete inventory reserves;
|
| ● |
assumptions used for leases;
|
| ● |
valuation of warrant liabilities;
|
| ● |
assumptions associated with revenue
recognition; and
|
| ● |
assumptions underlying the fair value used in the calculation of stock-based compensation.
|
The Company bases these estimates on historical and anticipated results and trends
and on various other assumptions the Company believes are reasonable under the circumstances, including assumptions as to future events. Changes in estimates are recorded in the period in which they become known. Actual results could differ from
those estimates, and any such differences may be material to the Condensed Consolidated Financial Statements.
Inventory, Net
Inventory is stated at the lower of cost or net realizable value with
cost determined using the first-in, first-out method. Materials that may be utilized for either commercial or, alternatively, for research and development purposes, are classified as inventory. Amounts in inventory used for research and
development purposes are charged to research and development expense when the product enters the research and development process and can no longer be used for commercial purposes and, therefore, does not have an “alternative future use”
as defined in authoritative guidance.
The Company performs an assessment of the recoverability of capitalized inventory during each reporting period and, if needed, records an excess and obsolete
reserve against inventory to its estimated net realizable value in the period it is identified. For further discussion related to inventory, please refer to Note 5. Inventory, Net.
Warrant Liabilities
The Company’s outstanding warrants include publicly traded warrants (the “Public Warrants”) and warrants sold in a private placement (the “Private Warrants”). The
Public Warrants and Private Warrants meet the definition of a derivative and the Company recorded these warrants as long-term liabilities in the Condensed Consolidated Balance Sheets at fair value upon initial recognition, with subsequent
changes in their respective fair values recognized in the Condensed Consolidated Statements of Operations and Comprehensive Loss at each reporting date. For further discussion related to the Public Warrants and Private Warrants, please
refer to Note 11. Warrant Liabilities.
Revenue Recognition
The Company’s revenue is derived from sales of products and services. Product revenue is primarily generated from the sales of instruments and consumables used in protein sequencing and analysis. Service revenue is
primarily generated from service maintenance contracts including access to analysis software and advanced training for instrument use. The Company recognizes revenue when or as a customer obtains control of the promised goods and
services. The amount of revenue recognized reflects the consideration to which the Company expects to be entitled in exchange for these goods and services. This process involves identifying the contract with a customer, determining
the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue as the performance obligations have been
satisfied. The Company has made the accounting policy election allowed for under ASC 606-10-32-2A to exclude all sales taxes from transaction price. Revenue recognition for contracts with multiple deliverables is based on the
separate satisfaction of each distinct performance obligation within the contract. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or
together with other resources that are readily available to the customer and is separately identified in the contract. The Company allocates transaction price to the performance obligations in a contract with a customer based on the
relative standalone selling price of each performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not
observable through past transactions, the Company estimates the standalone selling price taking into account available information and specific factors such as competitive positioning, internal costs, profit objectives, and
internally approved pricing guidelines related to the performance obligation.
The Company considers performance obligation for sales of products satisfied upon shipment of the goods to the customer in accordance with the shipping
terms (either upon shipment or delivery), which is when control of the product is deemed to be transferred; this includes instruments and consumables. Customers generally do not have a right to return products, except for defective or
damaged products during the warranty period or unless prior written consent is provided. In instances where right of payment or transfer of title is contingent upon the customer’s acceptance of the product, revenue is deferred until
all acceptance criteria have been met. Revenues for service maintenance contracts, which start after the first year of purchase and are considered as service type warranties that effectively extend the standard first-year service
coverage at the customer’s option are recognized ratably over the contract service period as these services are performed evenly over time. Revenues for advanced training is recognized at a point in time upon satisfaction of the
underlying performance obligation. The Company typically provides a standard one-year warranty which covers defects
in materials, workmanship and manufacturing or performance conditions under normal use and service. The first year of the warranty of the products is considered an assurance-type warranty and is recorded as Cost of revenue within the
Condensed Consolidated Statements of Operations and Comprehensive Loss. The Company has determined the standard first-year warranty is not a distinct performance obligation.
The Company disaggregates revenue from contracts with customers by type of revenue. The Company believes product revenue and service revenue
aggregate the payor types by nature, amount, timing and uncertainty of its revenue streams. Total revenue generated from domestic and international sales was approximately $0.3 million and $0.2 million, respectively, for the three
months ended March 31, 2024. All revenue generated for the three months ended March 31, 2023 resulted from domestic sales.
Deferred Revenue
Deferred revenue is a contract liability that consists of customer payments received in advance of performance or billings in excess of revenue
recognized, net of revenue recognized from the balance at the beginning of the period.
Deferred revenue primarily consists of billings and payments received in advance of revenue
recognition from service maintenance contracts including software subscription, proof of concept services and advanced training, and is reduced as the revenue recognition criteria are met. Deferred revenue also includes proof of concept
services and advanced training provided to customers until the service has been performed. Deferred revenue is classified as current or non-current based on expected revenue recognition timing. Specifically, deferred revenue that will be
recognized as revenue within the succeeding 12-month period is recorded as current and is included within Accrued expenses and other current liabilities, and the portion of deferred revenue where revenue is expected to be recognized beyond
12 months from the reporting date is recorded as non-current deferred revenue and is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.
As of March 31, 2024, the Company had deferred revenue of $0.1 million included within Accrued expenses and other current liabilities
in the Company’s Condensed Consolidated Balance Sheets. As of March 31, 2024, amounts included within Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets were immaterial. The Company expects to recognize
approximately 30 % of its remaining performance obligations as revenue for the of the year ending December 31, 2024.
Stock-Based Compensation
Stock-based compensation expense for stock option grants with only service conditions is recognized on a straight-line basis over the requisite service period of the individual grants, which is generally the vesting period, based on the estimated grant date
fair values. Stock-based compensation expense for stock option grants subject to non-financing event performance conditions on an accelerated basis is recognized as though each vesting portion of the award was, in substance, a separate award.
Prior to the business combination
between HighCape Capital Acquisition LLC and Quantum-Si Incorporated in June 2021 (the “Business Combination”), the fair value of the shares of common stock underlying stock options had historically been determined by the Company’s board of
directors (the “Board”), with input from management and contemporaneous third-party valuations, as there was no public market for the common stock. Given the absence of a public trading market for the Company’s common stock, the Board exercised
reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each option grant date.
After the
completion of the Business Combination, the Company measures compensation expense for stock-based awards to employees, non-employees and directors based upon the awards’ initial grant-date fair values. Stock-based compensation expense for
stock options, restricted stock units and performance awards is recorded over the requisite service period. For awards with only a service condition, the Company expenses stock-based compensation using the straight-line method over the
requisite service period for the entire award. For awards with a market condition, the Company expenses the grant date fair value at the target over the vesting period regardless of the value the award recipients ultimately receive. The fair
value of restricted stock without a market condition is estimated using the current market price of the Company’s Class A common stock on the date of grant. The fair value of stock option grants with a market condition is estimated at the
date of grant using the Monte Carlo simulation model (“Monte Carlo”). The fair values of stock option grants are estimated as of the date of grant by applying the Black-Scholes option valuation model (“Black-Scholes”). The Black-Scholes and
Monte Carlo models incorporate assumptions as to stock price volatility, the expected life of options or restricted stock, a risk-free interest rate and dividend yield. The effect of forfeiture in compensation costs is recognized based on
actual forfeitures when they occur.
Black-Scholes is affected by the stock price on the date of the grant as well as assumptions regarding a number of highly complex and subjective variables. These variables include the expected term of
the option, expected risk-free interest rate, the expected volatility of Class A common stock, and expected dividend yield; each of which is described below. The assumptions for expected term and expected volatility are the two assumptions that
significantly affect the grant date fair value.
| ● |
Expected Term: The expected term using the “simplified” method, which is the simple average of the vesting period and the contractual term.
|
| ● | Risk-free Interest Rate: The risk-free interest rate for periods within the expected term of the awards is based on the U.S. Treasury yield curve in effect at the time of the grant. |
| ● |
Expected Stock Price Volatility: The Company determined expected annual equity volatility based on the historical volatility of its Class A common stock.
|
| ● |
Dividend Yield: Because the Company has never paid a dividend and does not expect to begin doing so in the foreseeable future, the Company assumes
|
| ● |
Exercise Price: The exercise price is taken directly from the grant notice issued to employees and nonemployees.
|
Recently Issued Accounting Pronouncements
In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which expands income tax disclosure requirements to include additional information related to the rate reconciliation of effective tax rates to statutory rates, as well as additional disaggregation of taxes paid in both
U.S. and foreign jurisdictions. The amendments in ASU 2023-09 also remove disclosures related to certain unrecognized tax benefits and deferred taxes. The amendments are effective for fiscal years beginning after December 31, 2024. The amendments
may be applied prospectively or retrospectively. The Company is currently evaluating the effect ASU 2023-09 may have on its Consolidated Financial Statements and disclosures.
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which requires enhanced
disclosures about significant segment expenses. In addition, the ASU clarified that single reportable segment entities must apply Topic 280 in its entirely. The ASU does not change how an entity identifies its operating segments, aggregates those
operating segments, or applies the quantitative thresholds to determine its reportable segments. The ASU is required to be applied retrospectively to all periods presented in the financial statements and is effective for fiscal years beginning
after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. The Company is currently evaluating the effect ASU 2023-07 may have on its Consolidated Financial Statements and disclosures.
Note 3. Investments in Marketable Securities
As of March 31, 2024 and December 31, 2023, the Company’s investments in marketable securities were determined to be available-for-sale securities. Gross unrealized
gains or losses resulting from changes in the fair value of available-for-sale securities for the three months ended March 31, 2024 were less than $0.1
million. There were no
Dividend and interest income from marketable securities and realized and unrealized gain on marketable securities, net, related to the Company’s available-for sale
securities for the three months ended March 31, 2024 and trading securities for the three months ended March 31, 2023 were as follows (in thousands):
|
2024
|
2023
|
|||||||
|
Dividend and interest income from marketable securities
|
$
|
|
$
|
|
||||
|
Gain on marketable securities, net
|
$
|
|
$
|
|
||||
The following is a summary of the Company’s available-for-sale securities recorded within Marketable securities in the
Condensed Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023 (in thousands):
|
March 31, 2024
|
||||||||||||||||
|
Amortized
Costs
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair
Value
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Short-term marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
|
Commercial paper
|
|
|
(
|
)
|
|
|||||||||||
|
Total
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||||
|
December 31, 2023
|
||||||||||||||||
|
Amortized
Costs
|
Gross
Unrealized
Gains
|
Gross
Unrealized
Losses
|
Fair
Value
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Short-term marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
The fair values of the Company’s available-for-sale securities included within Marketable securities in the Condensed
Consolidated Balance Sheets as of March 31, 2024 and December 31, 2023, by remaining contractual maturity, are as follows (in thousands):
|
March 31, 2024
|
||||||||||||||||
|
One Year
or Less
|
Over
One Year
Through
Five Years
|
Over
Five Years
|
Total
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Short-term marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
December 31, 2023
|
||||||||||||||||
|
One Year
or Less
|
Over
One Year
Through
Five Years
|
Over
Five Years
|
Total
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Short-term marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Total
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
Note 4. Fair
Value of Financial Instruments
Fair value estimates of financial instruments are made at a specific point in time, based on relevant information about financial markets and specific financial
instruments. As these estimates are subjective in nature, involving uncertainties and matters of significant judgment, they cannot be determined with precision. Changes in assumptions can significantly affect estimated fair value.
The Company measures fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an
orderly transaction between market participants at the reporting date. The Company utilizes a three-tier hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value:
| ● |
Level 1: Valuations based on quoted prices in active markets for identical assets or liabilities that an entity has
the ability to access.
|
| ● |
Level 2: Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or
liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
|
| ● |
Level 3: Valuations based on quoted prices for similar assets or liabilities, quoted prices for identical assets or liabilities in markets that are not active, or other
inputs that are observable or can be corroborated by observable data for substantially the full term of the assets or liabilities.
|
The carrying value of cash and cash equivalents, accounts payable and accrued expenses and other current liabilities approximates their fair values due to the short-term or on demand nature of
these instruments. At March 31, 2024 and December 31, 2023, the Company’s investment portfolio included available-for-sale securities which were comprised of money market funds, U.S. treasury bills and commercial paper. The majority of the
Company’s cash equivalents and short-term investments consist of instruments classified as Level 1. However, the Company has commercial paper that is classified as Level 2 due to the fair value for these instruments being determined by
utilizing observable inputs in similar assets or identical assets in non-active markets. There were no transfers between fair value measurement levels for the three months ended March 31, 2024 and 2023.
Warrants are recorded as Warrant liabilities in the Condensed Consolidated Balance Sheets. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented as Change in fair
value of warrant liabilities in the Condensed Consolidated Statements of Operations and Comprehensive Loss.
The Public Warrants and Private Warrants were carried at fair value as of March 31, 2024 and December
31, 2023. The Public Warrants were valued using Level 1 inputs as they are traded in an active market. The Private Warrants were valued using a binomial lattice model. The primary unobservable input utilized in determining the fair value of the
Private Warrants was the expected volatility of the Company’s Class A common stock. The expected volatility was based on consideration of the implied volatility from the Company’s own Public Warrant pricing and on the historical volatility
observed at guideline public companies. As of March 31, 2024, the significant assumptions used in preparing the binomial lattice model for valuing the Private Warrants liability include (i) volatility of 89.9 %, (ii) risk-free interest rate of 4.50 %, (iii) strike price of $11.50 , (iv) fair value of Class A common stock of $1.97 ,
and (v) expected life of 2.2 years. As of December 31, 2023, the significant assumptions used in preparing the binomial lattice
model for valuing the Private Warrants liability include (i) volatility of 92.1 %, (ii) risk-free interest rate of 4.10 %, (iii) strike price of $11.50 ,
(iv) fair value of Class A common stock of $2.01 , and (v) expected life of 2.4 years. There were no
The following table summarizes the Company’s assets and liabilities that are measured at fair value on a recurring basis, by level, within the fair value hierarchy (in
thousands):
|
March 31, 2024
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
|
|
|
|
||||||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Total assets at fair value on a recurring basis
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Liabilities:
|
||||||||||||||||
|
Public Warrants
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Private Warrants
|
|
|
|
|
||||||||||||
|
Total liabilities at fair value on a recurring basis
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
December 31, 2023
|
||||||||||||||||
|
Level 1
|
Level 2
|
Level 3
|
Total
|
|||||||||||||
|
Financial Assets:
|
||||||||||||||||
|
Cash equivalents:
|
||||||||||||||||
|
Money market funds
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
U.S. Treasury securities
|
|
|
|
|
||||||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Marketable securities:
|
||||||||||||||||
|
U.S. Treasury securities
|
|
|
|
|
||||||||||||
|
Commercial paper
|
|
|
|
|
||||||||||||
|
Total assets at fair value on a recurring basis
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Liabilities:
|
||||||||||||||||
|
Public Warrants
|
$
|
|
$
|
|
$
|
|
$
|
|
||||||||
|
Private Warrants
|
|
|
|
|
||||||||||||
|
Total liabilities at fair value on a recurring basis
|
$
|
|
$
|
|
$
|
|
$
|
|||||||||
Note 5. Inventory, Net
Inventory, net, consists of the following as of March 31, 2024 and December 31, 2023 (in thousands):
|
March 31, 2024
|
December 31, 2023
|
|||||||
|
Raw materials
|
$
|
|
$
|
|
||||
|
Work in progress
|
|
|
||||||
|
Finished goods
|
|
|
||||||
|
Total inventory
|
|
|
||||||
|
Inventory reserves
|
(
|
)
|
(
|
)
|
||||
|
Total inventory, net
|
$
|
|
$
|
|
||||
As of March 31, 2024 and December 31, 2023, the Company included $4.0 million and $3.4 million, respectively, of reserves against inventory in the Condensed Consolidated Balance Sheets related to product that was considered to not have an
alternative future use. For the three months ended March 31, 2024, the Company recorded $0.6 million reserve against
inventory in Research and Development expenses in the Condensed Consolidated Statements of Operations and Comprehensive Loss related to product that was considered to not have an alternative future use. There was no such reserve recorded against inventory for the three months ended March 31, 2023.
Note 6. Property and Equipment, Net
Property and equipment, net, consists
of the following as of March 31, 2024 and December 31, 2023 (in thousands):
|
March 31, 2024
|
December 31, 2023
|
|||||||
|
Laboratory and production equipment
|
$
|
|
$
|
|
||||
|
Computer equipment
|
|
|
||||||
|
Purchased software
|
|
|
||||||
|
Furniture and fixtures
|
|
|
||||||
| Leasehold improvements | ||||||||
|
Construction in process
|
|
|
||||||
|
Subtotal
|
|
|
||||||
|
Less: Accumulated depreciation and amortization
|
(
|
)
|
(
|
)
|
||||
|
Property and equipment, net
|
$
|
|
$
|
|
||||
Depreciation and amortization expense was $1.1 million
and $0.8 million for the three months ended March 31, 2024 and 2023, respectively. The Company had no disposals of property and equipment for the three months ended March 31, 2024. Losses on disposals of property and equipment were immaterial for
three months ended March 31, 2023. No
Note 7. Leases
Lease-related costs for the three months ended March 31, 2024 and 2023 are as follows (in thousands):
|
2024
|
2023
|
|||||||
|
Operating lease cost
|
$
|
|
$
|
|
||||
|
Variable lease cost
|
|
|
||||||
|
Total lease cost
|
$
|
|
$
|
|
||||
As of March 31,
2024, the maturities of the operating lease liabilities and a reconciliation to the present value of lease liabilities were as follows (in thousands):
|
Remaining
Lease Payments
|
||||
|
Remainder of 2024
|
$
|
|
||
|
2025
|
|
|||
|
2026
|
|
|||
|
2027
|
|
|||
|
2028
|
|
|||
|
Thereafter
|
|
|||
|
Total remaining undiscounted lease payments
|
$
|
|
||
|
Less: Imputed interest
|
(
|
)
|
||
|
Less: Lease incentives (1)
|
(
|
)
|
||
|
Total operating lease liabilities
|
|
|
||
| Less: current portion | ( |
) | ||
|
Long-term operating lease liabilities
|
$ |
|||
| Weighted-average remaining lease term (in years) | ||||
| Weighted-average discount rate | % | |||
|
(1)
|
|
The following table provides certain cash flow and supplemental cash flow information related to the Company’s lease liabilities for the three months ended March 31,
2024 and 2023 (in thousands):
|
2024
|
2023
|
|||||||
|
Operating cash paid to settle operating lease liabilities
|
$
|
|
$
|
|
||||
In December 2021, the Company signed a 10 -year lease for approximately 67,000 square feet of space in New Haven, Connecticut. The lease commenced on January 8, 2022 with rent payments beginning on July 7, 2022. Under
the lease, the landlord agreed to reimburse the Company for up to $9.1 million in improvements to the space, to be used for such
improvements as the Company deems “necessary or desirable”. On September 13, 2022, the Company filed a lawsuit against the landlord, alleging that the landlord has: (i) refused to reimburse the Company for costs related to improvements already
incurred and submitted, (ii) delayed the Company’s completion of improvements, in order to avoid reimbursing the costs of those improvements, and (iii) improperly rejected the Company’s proposed improvement plans. The Company accounted for
these lease incentives as an offset to the lease liability recorded at the inception of the lease. Although the Company believes it is contractually entitled to the $9.1 million of lease incentives, based on the current status of the litigation, the Company cannot determine the likely outcome or estimate the impact on such carrying values.
The Company incurred and recognized total leasehold improvements of approximately $1.6
Note 8. Accrued
Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consist of the following as of March 31, 2024 and December 31, 2023 (in thousands):
|
March 31, 2024
|
December 31, 2023
|
|||||||
| Restructuring costs | $ |
$ |
||||||
|
Legal fees
|
|
|
||||||
| Royalties |
||||||||
|
Other
|
|
|
||||||
|
Total accrued expenses and other current liabilities
|
$
|
|
$
|
|
||||
Note 9. Stock-based Compensation
Equity Incentive
Plan
The Quantum-Si Incorporated 2021 Equity Incentive Plan (the “2021 Plan”) provides for grants of stock options, stock appreciation rights, restricted stock,
restricted stock units, and other stock or cash-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing consulting or advisory services for the Company, are eligible for grants under
the 2021 Plan. As of March 31, 2024 there were 14,661,839 shares available for future grant under the 2021 Plan.
Inducement Equity Incentives
On May 8, 2023, the Company adopted the 2023 Inducement Equity Incentive Plan (the “2023 Inducement Plan”) to reserve 3,000,000 shares of its Class A common stock to be used exclusively for grants of awards to employees that were not previously employees or directors of the Company as a
material inducement to such individuals’ entry into employment with the Company within the meaning of Rule 5635(c)(4) of the Nasdaq Listing Rules. The terms and conditions of the 2023 Inducement Plan are substantially similar to those of the
2021 Plan. As of March 31, 2024, there were 60,250 shares remaining available for
issuance under the 2023 Inducement Plan.
Stock Options
During the three months ended March 31, 2024, the Company did grant any stock options to participants. Stock-based compensation related to stock options for the three months ended March 31, 2024 and 2023 was $1.3 million and $2.3 million,
respectively.
A summary of the stock option activity is presented in the table below:
|
Number of
Options
|
Weighted Average
Exercise Price
(per share)
|
Weighted Average
Remaining
Contractual Life
(in years)
|
Aggregate
Intrinsic Value
(in thousands)
|
|||||||||||||
|
Outstanding at December 31, 2023
|
|
$
|
|
|
$
|
|
||||||||||
|
Granted
|
|
|
||||||||||||||
|
Exercised
|
|
|
||||||||||||||
|
Forfeited
|
(
|
)
|
|
|||||||||||||
| Expired |
( |
) | ||||||||||||||
|
Outstanding at March 31, 2024
|
|
$
|
|
|
$
|
|
||||||||||
|
Exercisable at March 31, 2024
|
|
$
|
|
|
$
|
|
||||||||||
|
Vested and expected to vest at March 31, 2024
|
|
$
|
|
|
$
|
|
||||||||||
Modification of Performance Stock Options
In November 2022 and May 2023, the Company granted 2,780,000 and 1,000,000 performance-based stock option awards to its Chief Executive Officer and Chief Financial Officer, respectively. The vesting of these awards are
subject to continued service to the Company and certain market conditions. The market conditions require the Company’s Class A common stock trade above specified levels for a certain periods of time. The fair values of the awards were
estimated at the grant date using the Monte Carlo simulation model.
On March 15, 2024, the market conditions that trigger the vesting
of these performance-based stock option awards were modified. The modified market conditions require the Company’s Class A common stock to trade above specified levels for certain defined periods of time that are different from the original
awards. The Company accounted for the modifications as modifications of market conditions. The total incremental stock-based compensation expense to be recognized for these awards is $2.4 million within Selling, general and administrative operating expenses in the Condensed
Consolidated Statements of Operations and Comprehensive Loss. Incremental stock-based compensation expense for the three months ended March 31, 2024 was . There were no such
modifications to performance-based stock option awards for the three months ended March 31, 2023.
Restricted Stock Units
During the three months ended March 31, 2024, the Company granted 5,406,164 restricted stock unit (“RSU”) awards. Stock-based compensation related to RSU awards for the three months ended March 31, 2024 and 2023
was $0.3 million and $1.6
million, respectively.
A summary of the RSU activity is presented in the table below:
|
Number of Shares
Underlying RSUs
|
Weighted Average
Grant-Date Fair
Value (per share)
|
|||||||
|
Nonvested RSUs at December 31, 2023
|
|
$ | ||||||
|
Granted
|
|
|
||||||
|
Vested
|
(
|
)
|
|
|||||
|
Forfeited
|
(
|
)
|
|
|||||
|
Nonvested RSUs at March 31, 2024
|
|
|
|
|||||
Stock-based compensation is allocated to Research and development and Selling, general and administrative operating expenses in the Condensed Consolidated Statements
of Operations and Comprehensive Loss. Stock-based compensation expense for the three months ended March 31, 2024 and 2023 is as follows (in thousands):
|
2024
|
2023
|
|||||||
|
Research and development
|
$
|
|
$
|
|
||||
|
Selling, general and administrative
|
|
|
||||||
|
Total stock-based compensation
|
$
|
|
$
|
|
||||
As of March 31, 2024 total unrecognized stock-based compensation related to stock options and RSUs was $24.4 3.3 years.
Note 10. Net Loss Per Share
The Company presents both basic earnings per share (“EPS”) and diluted EPS. Basic net loss per share is computed by dividing net loss by the weighted-average number
of shares of common stock outstanding for the period. Diluted net loss per share is computed by giving effect to all common share equivalents to the extent they are dilutive. Basic and diluted net loss per share was the same for each period
presented as the inclusion of all common share equivalents would have been anti-dilutive.
The following table presents the calculations for the three months ended March 31, 2024 and 2023 of basic and diluted net loss per share for the Company’s common
stock (in thousands, except per share amounts):
|
2024
|
2023
|
|||||||
|
Numerator
|
||||||||
|
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Numerator for basic and diluted EPS - loss attributable to common stockholders
|
$
|
(
|
)
|
$
|
(
|
)
|
||
|
Denominator
|
||||||||
|
Common stock
|
|
|
||||||
|
Denominator for basic and diluted EPS - weighted-average common stock
|
|
|
||||||
|
Basic and diluted net loss per share
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Additionally, net loss per share attributable to Class A and Class B common stockholders was the same on a basic and diluted basis, as the inclusion of all potential common equivalent shares
outstanding would have been anti-dilutive.
The following potential dilutive shares were excluded from the calculation of diluted net loss per share because their effect would be
anti-dilutive for the three months ended March 31, 2024 and 2023:
|
2024
|
2023
|
|||||||
|
Outstanding options to purchase common stock
|
|
|
||||||
|
Outstanding restricted stock units
|
|
|
||||||
|
Outstanding warrants
|
|
|
||||||
|
|
|
|||||||
Note 11. Warrant Liabilities
Public Warrants
As of March 31, 2024 and December 31, 2023, there were an aggregate of 3,833,319 one 11.50
Redemptions
At any time while the Public Warrants are exercisable, the Company may redeem not less than all of the outstanding Public Warrants:
| ● |
in whole and not in part;
|
| ● |
at a price of $
|
| ● |
upon not less than
|
| ● |
if, and only if, the closing price of the Company’s Class A common stock equals or exceeds $
|
If the foregoing conditions are satisfied and the Company issues a notice of redemption of the Public Warrants at $0.01 per warrant, each holder of Public Warrants will be entitled to exercise their Public Warrants prior to the scheduled redemption date.
If the Company calls the Public Warrants for redemption for $0.01
as described above, the Board may elect to require any holder that wishes to exercise their Public Warrants to do so on a “cashless basis.” If the Board makes such election, all holders of Public Warrants would pay the exercise price by surrendering
their warrants for the number of shares of Class A common stock equal to the quotient obtained by dividing (x) the product of the number of shares of Class A common stock underlying the warrants, multiplied by the excess of the “fair market value”
over the exercise price of the warrants by (y) the “fair market value”. For purposes of the redemption provisions of the warrants, the “fair market value” means the average last reported sale price of the Class A common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants.
The Public Warrants do not meet the criteria to be classified in stockholders’ equity as the exercise of the Public Warrants may be settled in cash upon the occurrence
of a tender offer or exchange offer in which the maker of the tender offer or exchange offer, upon completion of the tender offer or exchange offer, beneficially owns more than 50 % of the outstanding shares of the Company’s Class A common stock, even if it would not result in a change of control of the Company. This provision precludes the Public Warrants from being
classified in equity and thus they are classified as long-term liabilities in the Condensed Consolidated Balance Sheets.
Private Warrants
As of March 31, 2024 and December 31, 2023, there were 135,000 30 days after the
completion of the Business Combination, (ii) the Private Warrants will be exercisable for cash or on a cashless basis, at the holder’s option, and (iii) the Private Warrants are not subject to the Company’s redemption option at the price of $0.01 per warrant. The Private Warrants are subject to the Company’s redemption option at the price of $0.01 per warrant, provided the other conditions of such redemption are met, as described above. If the Private Warrants are held by a holder other than HighCape Capital
Acquisition LLC or any of its permitted transferees, the Private Warrants will be redeemable by the Company in all redemption scenarios applicable to the Public Warrants and exercisable by such holders on the same basis as the Public Warrants.
The
Private Warrants do not meet the criteria to be classified in stockholders’ equity as the terms of the warrants provide for potential changes to the settlement amounts depending upon the characteristics of the warrant holder, and, because the
holder of a warrant is not an input into the pricing of a fixed-for-fixed option on equity shares. This provision precludes the Private Warrants from being classified in equity and thus they are classified as long-term liabilities in the
Condensed Consolidated Balance Sheets.
The fair value of warrant liabilities was $1.0 million and $1.3 million as of March 31, 2024 and December 31, 2023, respectively. The Company
recognized gains of $0.3 million and $0.4
million for the three months ended March 31, 2024 and 2023, respectively, as a Change in fair value of warrant liabilities in the Condensed Consolidated Statements of Operations and Comprehensive Loss. There were no
Note 12. Restructuring
The Company committed to organizational restructurings during the first and third
quarters of 2023, designed to decrease its costs and create a more streamlined organization to support its business. As of March 31, 2024 and December 31, 2023, the Company recorded a restructuring liability of $0.2 million and $0.5 million,
respectively, which is included in Accrued expenses and other current liabilities in the Condensed Consolidated Balance Sheets.
The Company’s
restructuring costs, primarily for cash severance and other severance costs, are allocated to the following operating expense categories as follows (in thousands):
|
Research and
Development
|
Selling,
general and
administrative
|
Total
|
||||||||||
|
Balance as of December 31, 2023
|
$
|
|
$
|
|
$
|
|
||||||
|
Restructuring charges incurred(1)
|
|
|
|
|||||||||
|
Cash payments and other adjustments(1)
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
|
Balance as of March 31, 2024
|
$
|
|
$
|
|
$
|
|
||||||
|
Current liabilities
|
$
|
|
||||||||||
|
Long-term liabilities
|
|
|||||||||||
| Total liabilities as of March 31, 2024 |
$
|
|
||||||||||
| (1) |
|
The
Company’s restructuring activities are complete as of March 31, 2024 and the Company does no t expect to incur material additional
charges associated with these activities.
Note 13. Income Taxes
Income taxes for the three months ended March 31, 2024 and 2023 are recorded at the Company’s estimated annual effective income tax rate,
subject to adjustments for discrete events, if they occur. The Company’s estimated annual effective tax rate was 0.0 21.0 0.0
A valuation allowance is required when it is more likely than not that some portion or all of the Company’s deferred tax assets will not be realized. The realization
of deferred tax assets depends on the generation of sufficient future taxable income during the period in which the Company’s related temporary differences become deductible. Management believes that based on the earnings history of the Company, it
is more likely than not that the benefits of these assets will not be realized, and therefore, a full valuation allowance has been recorded against the Company’s net deferred tax assets as of March 31, 2024 and December 31, 2023.
Note 14. Related Party Transactions
Effective as of February 17, 2021, legacy Quantum-Si entered into a Master Services Agreement (“MSA”) with 4Catalyzer Corporation (“4C”), a company controlled by Dr. Jonathan Rothberg, the Chairman of the Board, pursuant to which the
Company may engage 4C to provide services such as general administration, facilities, information technology, financing, legal, human resources and other services, through future statements of work and under terms and conditions to be
determined by the parties with respect to any services to be provided. For the three months ended March 31, 2024 and 2023, the Company incurred $0.1
Effective October 1, 2022, the Company entered into a Protein Engineering Collaboration (the “New Collaboration”) with Protein Evolution, Inc. (“PEI”) to develop technology and
methods in the field of nanobodies and potentially other binders to produce novel biological reagents and related data. Dr. Rothberg serves as Chairman of the board of directors of PEI and the Rothberg family are controlling stockholders of
PEI. As of March 31, 2024, the amount due from PEI to the Company related to the New Collaboration was $0.2 million. As of December
31, 2023, the amount due from PEI to the Company related to the New Collaboration was $0.3 million.
Effective November 1, 2022, the Company entered into an Advisory Agreement with Dr. Rothberg (the “Advisory Agreement”), pursuant to which Dr. Rothberg serves as Chairman of the
Board, advises the Chief Executive Officer and the Board on strategic matters, and provides consulting, business development and similar services on matters relating to the Company’s current, future and potential scientific and strategic
initiatives and such other consulting services reasonably requested from time to time. Pursuant to the Advisory Agreement, as compensation for the services provided thereunder, in March 2023, the Company granted Dr. Rothberg an option to
purchase 250,000 shares of Class A common stock pursuant to the 2021 Plan. In connection with the Advisory Agreement, Dr. Rothberg’s
title was changed from Executive Chairman to Chairman of the Board.
Note 15. Commitments and Contingencies
Commitments
Licenses related to certain intellectual property:
The Company licenses certain intellectual property, some of which may be utilized in its current or future product offerings. To preserve the right to use such
intellectual property, the Company is required to make annual minimum fixed payments totaling approximately $0.1 million as well as
royalties based on net sales if the royalties exceed annual minimum fixed payments. As of March 31, 2024 and December 31, 2023, the Company had accrued royalties of approximately $0.1
Other commitments:
The Company sponsors a 401(k) defined contribution plan covering all eligible U.S. employees (the “401(k) Plan”). Contributions to the 401(k) Plan are discretionary.
The Company did no
Contingencies
The Company is subject to claims in the ordinary course of business. Except as discussed below, the Company is not currently a party to any pending or threatened
litigation, the outcome of which would be expected to have a material adverse effect on its financial condition, results of operations, or cash flows. The Company accrues contingent liabilities to the extent the liability is probable and estimable.
In April 2023, the Company informed the contract manufacturer that had manufactured its Platinum® and Carbon™ instruments that it intended to wind down
the relationship and transition to a different contract manufacturer. In October 2023, the former contract manufacturer filed a complaint against the Company in the State of Texas alleging breach of contract and made claims for economic damage
and attorney costs. In January 2024, the suit was withdrawn and refiled in the State of Minnesota alleging similar claims. Although it is not possible to determine the potential financial exposure associated with the alleged claim at this time
given its early stage, the Company believes it has a meritorious defense and intends to vigorously defend against all claims asserted in the complaint.
The Company enters into agreements that contain indemnification provisions with other parties in the ordinary course of business, including business partners,
investors, contractors, and the Company’s officers, directors and certain employees. The Company has agreed to indemnify and defend the indemnified party claims and related losses suffered or incurred by the indemnified party from actual or
threatened third-party claims because of the Company’s activities or non-compliance with certain representations and warranties made by the Company. It is not possible to determine the maximum potential loss under these indemnification provisions
due to the Company’s limited history of prior indemnification claims and the unique facts and circumstances involved in any particular case. To date, losses recorded in the Condensed Consolidated Statements of Operations and Comprehensive Loss in
connection with the indemnification provisions have not been material.
| Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our condensed consolidated results of
operations and financial condition. The discussion should be read in conjunction with (i) the unaudited Condensed Consolidated Financial Statements and notes thereto contained in this Quarterly Report on Form 10-Q, (ii) the Consolidated Financial
Statements and notes thereto for the year ended December 31, 2023 contained in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission (the “SEC”) on February 29, 2024 and (iii) our
other public reports filed with the SEC. This discussion contains forward looking statements and involves numerous risks and uncertainties, including, but not limited to, those described in the “Risk Factors” section of our Annual Report on Form
10-K for the year ended December 31, 2023 and this Quarterly Report on Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements. Unless the context otherwise requires, references to “we”, “us”, “our”,
the “Company” or “Quantum-Si” are intended to mean the business and operations of Quantum-Si Incorporated and its consolidated subsidiaries. The unaudited Condensed Consolidated Financial Statements for the three months ended March 31, 2024 and
2023 present the financial position and results of operations of Quantum-Si Incorporated and its consolidated subsidiaries.
Overview
We are an innovative life sciences company with the mission of transforming single-molecule analysis and democratizing its use by providing researchers and clinicians access to the proteome, the set
of proteins expressed within a cell. We have developed a proprietary universal single-molecule detection platform that we are first applying to proteomics to enable NGPS, the ability to sequence proteins in a massively parallel fashion (rather
than sequentially, one at a time), that can be used for the study of nucleic acids. Our platform was designed to offer an end-to-end workflow including both sample preparation and sequencing and is comprised of our Platinum® NGPS instrument, the Platinum Analysis Software service, and reagent kits and proprietary semiconductor chips for use with our Platinum® instrument. We began a controlled launch of the Platinum® instrument in December 2022 and subsequently
initiated a full commercial launch at the end of the first quarter of 2024.
Now that our Platinum® and Platinum Analysis Software system has launched, we intend to follow a systematic, phased
approach to continue to successfully launch updates to our platform. We believe we are the first company to successfully enable NGPS on a semiconductor chip, thus digitizing a massive proteomics opportunity, which allows for a massively parallel
solution at the ultimate level of sensitivity -single-molecule detection. We believe our platform, which is designed to streamline sequencing and data analysis at a lower instrument cost than legacy proteomic solutions, could allow our product to
have wide utility across the study of the proteome. For example, we believe our platform could be used for biomarker discovery and disease detection, pathway analysis, immune response, vaccine development, quality assurance and quality control,
among other applications.
Results of Operations for the Three Months Ended March 31, 2024 as Compared to the Three Months Ended March 31, 2023
The following table presents the unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2024 and 2023 (dollars in thousands):
|
|
Three months ended March 31,
|
|||||||||||||||
|
|
2024
|
2023
|
$ Change
|
% Change
|
||||||||||||
|
Revenue:
|
||||||||||||||||
|
Product
|
$
|
428
|
$
|
251
|
$
|
177
|
70.5
|
%
|
||||||||
|
Service
|
29
|
3
|
26
|
866.7
|
%
|
|||||||||||
|
Total revenue
|
457
|
254
|
203
|
79.9
|
%
|
|||||||||||
|
|
||||||||||||||||
|
Cost of revenue
|
188
|
130
|
58
|
44.6
|
%
|
|||||||||||
|
|
||||||||||||||||
|
Gross profit
|
269
|
124
|
145
|
116.9
|
%
|
|||||||||||
|
Operating expenses:
|
||||||||||||||||
|
Research and development
|
12,101
|
18,167
|
(6,066
|
)
|
(33.4
|
)%
|
||||||||||
|
Selling, general and administrative
|
11,528
|
11,178
|
350
|
3.1
|
%
|
|||||||||||
|
Total operating expenses
|
23,629
|
29,345
|
(5,716
|
)
|
(19.5
|
)%
|
||||||||||
|
Loss from operations
|
(23,360
|
)
|
(29,221
|
)
|
5,861
|
(20.1
|
)%
|
|||||||||
|
Dividend and interest income
|
3,574
|
2,219
|
1,355
|
61.1
|
%
|
|||||||||||
|
Gain on marketable securities, net
|
-
|
2,942
|
(2,942
|
)
|
(100.0
|
)%
|
||||||||||
|
Change in fair value of warrant liabilities
|
319
|
391
|
(72
|
)
|
(18.4
|
)%
|
||||||||||
|
Other (expense) income, net
|
(7
|
)
|
58
|
(65
|
)
|
(112.1
|
)%
|
|||||||||
|
Loss before provision for income taxes
|
(19,474
|
)
|
(23,611
|
)
|
4,137
|
(17.5
|
)%
|
|||||||||
|
Provision for income taxes
|
-
|
-
|
-
|
nm
|
||||||||||||
|
Net loss
|
$
|
(19,474
|
)
|
$
|
(23,611
|
)
|
$
|
4,137
|
(17.5
|
)%
|
||||||
Revenue, Cost of Revenue and Gross Profit
Revenue is derived from sales of products and services. Product revenue is generated from the following sources: (i) sales of our Platinum® instrument, (ii) consumables, which consist of sales of our library, sequencing reagents and semiconductor chips, and (iii) freight revenue, which is recognized upon shipment. Service revenue is generated from
service maintenance contracts including Platinum Analysis Software access, and advanced training for instrument use.
Cost of revenue primarily consists of product and service costs including material costs, personnel costs and benefits, inbound and outbound freight, packaging, warranty replacement costs, royalty
costs, facilities costs, depreciation and amortization expense, and inventory excess and obsolescence reserves.
Revenue, Cost of revenue and Gross profit for the three months ended March 31, 2024 and 2023 are as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Total revenue
|
$
|
457
|
$
|
254
|
$
|
203
|
79.9
|
%
|
||||||||
|
Cost of revenue
|
188
|
130
|
58
|
44.6
|
%
|
|||||||||||
|
Gross profit
|
$
|
269
|
$
|
124
|
$
|
145
|
116.9
|
%
|
||||||||
|
Gross profit margin
|
58.9
|
%
|
48.8
|
%
|
||||||||||||
Total revenue for the three months ended March 31, 2024 increased $0.2 million, or 79.9%, for the sale of Platinum®
instruments, related reagent kits and service maintenance contracts as compared to the same period in 2023. Cost of revenue recognized for the three months ended March 31, 2024 increased $0.1 million, or 44.6%, as compared to the same period in
2023. Gross profit increased $0.1 million, or 116.9%, for the three months ended March 31, 2024. We began a controlled launch of the Platinum® instrument and started
to take orders in December 2022. We subsequently began limited commercial shipments of Platinum® in January 2023 and subsequently initiated a full commercial launch at
the end of the first quarter of 2024.
Research and Development Expenses
Research and development expenses primarily consist of personnel costs and benefits, stock-based compensation, lab supplies, consulting and professional services, fabrication services, charges
related to product without an alternative future use, facilities costs, software, and other outsourced expenses. Research and development expenses are recognized as incurred. Our research and development expenses are primarily related to
developing new products and services.
Research and development expenses for the three months ended March 31, 2024 and 2023 are as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Research and development
|
$
|
12,101
|
$
|
18,167
|
$
|
(6,066
|
)
|
(33.4
|
)%
|
|||||||
Research and development expenses decreased by $6.1 million, or 33.4%, for the three months ended March 31, 2024 compared to the same period in 2023. This decrease was primarily due to a $4.0 million
decrease in fabrication and outsourced services and a $1.7 million decrease in payroll and payroll-related costs, primarily driven by restructuring activities that occurred in 2023 and personnel costs that were capitalized for the three months
ended March 31, 2024.
Selling, General and Administrative Expenses
Selling, general and administrative expenses primarily consist of personnel costs and benefits, stock-based compensation, patent and filing fees, consulting and professional services, legal and
accounting services, facilities costs, depreciation and amortization expense, insurance and office expenses, product advertising and marketing.
Selling, general and administrative expenses for the three months ended March 31, 2024 and 2023 are as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Selling, general and administrative
|
$
|
11,528
|
$
|
11,178
|
$
|
350
|
3.1
|
%
|
||||||||
Selling, general and administrative expenses increased $0.4 million, or 3.1%, for the three months ended March 31, 2024 as compared to the same period in 2023. This was primarily due to a $0.9 million
increase in legal fees and a $0.4 million increase in marketing expenses incurred as part of our increased commercialization efforts, partially offset by $0.9 million net decrease in personnel costs and a $0.4 million decrease in insurance costs.
Dividend and Interest Income
In 2024, dividend and interest income is derived primarily from fixed income securities and money market funds. In 2023, dividend and interest income was derived from mutual funds.
Dividend and interest income for the three months ended March 31, 2024 and 2023 are as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Dividend and interest income
|
$
|
3,574
|
$
|
2,219
|
$
|
1,355
|
61.1
|
%
|
||||||||
Dividend and interest income increased by $1.4 million, or 61.1%, for the three months ended March 31, 2024 as compared to the same period in 2023. The increase was a result of higher dividends and
interest earned on invested balances in marketable securities.
Gain on Marketable Securities, Net
Gain on marketable securities, net, for the three months ended March 31, 2024 and 2023 is as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Gain on marketable securities, net
|
$
|
-
|
$
|
2,942
|
$
|
(2,942
|
)
|
(100.0
|
)%
|
|||||||
There was no Gain on marketable securities, net, for the three months ended March 31, 2024 as compared to a gain of $2.9 million for the same period in 2023. The prior year gains were primarily
related to market adjustments of investments in marketable securities, which consisted of fixed income mutual funds.
Change in Fair Value of Warrant Liabilities
The warrant liabilities were recorded at fair value as part of the business combination between HighCape Capital Acquisition LLC and Quantum-Si Incorporated in June 2021 (the “Business
Combination”). Change in fair value of warrant liabilities primarily consists of the change in the fair value of our Public Warrants and Private Warrants.
Change in warrant liabilities for the three months ended March 31, 2024 and 2023 is as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Change in fair value of warrant liabilities
|
$
|
319
|
$
|
391
|
$
|
(72
|
)
|
(18.4
|
)%
|
|||||||
The fair value of warrant liabilities decreased $0.1 million, or 18.4%, for the three months ended March 31, 2024 as compared to the same period in 2023. This decrease was primarily driven by the
decrease in the underlying trading price of our Class A common stock experienced during the three months ended March 31, 2024.
Other (Expense) Income, Net
Other (expense) income, net, for the three months ended March 31, 2024 and 2023 are as follows (dollars in thousands):
|
2024
|
2023
|
$ Change
|
% Change
|
|||||||||||||
|
Other (expense) income, net
|
$
|
(7
|
)
|
$
|
58
|
$
|
(65
|
)
|
(112.1
|
)%
|
||||||
Other (expense) income, net decreased by $0.1 million, or 112.1%, for the three months ended March 31, 2024 as compared to the same period for 2023.
Liquidity and Capital Resources
The following table presents a summary of our consolidated cash flows for operating, investing, and financing activities for the three months ended March 31, 2024 and 2023, (in thousands):
|
|
Three months ended March 31,
|
|||||||
|
|
2024
|
2023
|
||||||
|
Net cash (used in) provided by:
|
||||||||
|
Net cash used in operating activities
|
$
|
(23,208
|
)
|
$
|
(28,698
|
)
|
||
|
Net cash (used in) provided by investing activities
|
(57,428
|
)
|
26,039
|
|||||
|
Net cash used in financing activities
|
(56
|
)
|
-
|
|||||
|
Effect of exchange rate changes on cash and cash equivalents
|
(5
|
)
|
-
|
|||||
|
Net change in cash and cash equivalents
|
$
|
(80,697
|
)
|
$
|
(2,659
|
)
|
||
Net cash used in operating activities
The net cash used in operating activities during the three months ended March 31, 2024, was $23.2 million compared to $28.7 million for the same period in 2023. This $5.5 million decrease was
primarily driven by our operating results which resulted in a $3.1 million decrease in net cash used year-over-year as well as a decrease of $2.4 million in net cash used resulting from changes in operating assets and liabilities. Timing of cash
receipts and cash payments in the ordinary course of business caused operating cash flow to fluctuate from period to period.
Net cash (used in) provided by investing activities
During the three months ended March 31, 2024, net cash used in investing activities was $57.4 million compared to net cash provided by investing activities of $26.0 million for the same period in
2023. This change was due primarily due to an increase in purchases of marketable securities of $78.8 million as well as a $7.0 million decrease in proceeds from the sales of marketable securities.
Net cash used in financing activities
During the three months ended March 31, 2024, net cash used in financing activities was $0.1 million. The net cash used primarily consisted of deferred offering costs paid for the Shelf Registration
Statement and the ATM Offering, both of which are defined and described below. There were no financing activities during the three months ended March 31, 2023.
Liquidity Outlook
Since our inception, we have funded our operations primarily with proceeds from the issuance of equity to private investors, as well as with the proceeds received from the closing of the Business
Combination on June 10, 2021. Additionally, we began to generate revenue during 2023 from commercial sales of our Platinum® instrument. Our primary uses of liquidity
have been operating expenses, capital expenditures and our acquisition of certain assets. Cash flows from operations have been historically negative as we continue to invest in the development of our technology in NGPS. Going forward, we anticipate
debt or equity offerings will be the primary source of funds to support our operating needs and capital expenditures until we reach scale of our commercial operations. We expect to incur negative operating cash flows on an annual basis for the
foreseeable future until such time that we can scale our revenue growth.
We expect that our existing cash and cash equivalents and investments in marketable securities, together with revenue from the sale of our products and services, will be sufficient to meet our
liquidity, capital expenditure, and anticipated working capital requirements and fund our operations for at least the next 12 months. We expect to use our cash and cash equivalents and investments in marketable securities and funds from revenue
generated to invest in our continued commercialization efforts, to further invest in research and development, for other operating expenses, business acquisitions and for working capital and general corporate purposes.
As of March 31, 2024, we had cash and cash equivalents and investments in marketable securities totaling $235.4 million. Our future capital requirements may vary from those currently planned and will
depend on various factors including the pace and success of product commercialization.
Our ongoing commercialization of Platinum® as well as our continuing research and development efforts to enhance our
Platinum® instrument may require an accelerated amount of spending to enhance the sales and marketing teams, continue to drive development, and build inventory. Other
factors that could accelerate cash needs include: (i) delays in achieving scientific and technical milestones, (ii) unforeseen capital expenditures and fabrication costs related to manufacturing for commercialization, (iii) changes we may make in
our business or commercialization strategy, (iv) costs of running a public company, (v) other items affecting our forecasted level of expenditures and use of cash resources, including potential acquisitions, and (vi) increased product and service
costs.
In August 2023, we filed a $150 million Shelf Registration Statement (the “Shelf Registration Statement”), which became effective on August 22, 2023.
In August 2023, we also entered into an Equity Distribution Agreement (“EDA”) with an outside placement agent (the “Agent”), under which we may,
from time to time, sell shares of our Class A common stock under the ATM Offering. The Shelf Registration Statement includes a prospectus supplement covering the offering, issuance and sale of up to $75 million of our Class A common stock, from
time to time, in at-the-market offerings through the Agent (the “ATM Offering”). The shares to be sold under the EDA may be issued and sold pursuant to the Shelf Registration Statement. The EDA also provides that the Agent will be entitled to
compensation for its services in an amount up to 3.0% of the gross proceeds from the sales of shares sold through the Agent under the EDA. We have no obligation to sell any shares under the EDA and may at any time suspend solicitation and offers
under the EDA. To date, we have not issued or sold any shares of our Class A common stock under the ATM Offering.
In the future, we may be unable to obtain any required additional financing on terms favorable to us, if at all. If adequate funds are not available to us on acceptable terms or otherwise, we may be
unable to successfully develop or enhance products and services, respond to competitive pressure or take advantage of acquisition opportunities, any of which could have a material adverse effect on our business, financial condition, operating
results and cash flows.
Contractual Obligations
We lease certain facilities and equipment under non-cancellable lease agreements that expire at various dates through 2032. As of March 31, 2024, the future payments, before adjustments for tenant incentives, under
leases was approximately $30.0 million.
Licenses related to certain intellectual property
We license certain intellectual property, some of which may be utilized in our current or future product offerings. To preserve the right to use such intellectual property, we are required to make
annual minimum fixed payments totaling approximately $0.1 million as well as royalties based on net sales if the royalties exceed annual minimum fixed payments.
Critical Accounting Policies and Significant Judgments and Estimates
Our management’s discussion and analysis of our financial condition and results of operations is based on our unaudited Condensed Consolidated Financial Statements, which have been prepared in
accordance with accounting principles generally accepted in the United States of America. The preparation of these unaudited Condensed Consolidated Financial Statements requires us to make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited Condensed Consolidated Financial Statements, as well as expenses incurred during the reporting periods. Our estimates are based on our
historical experience and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about items that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions. Please refer to our critical accounting policies as disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023 and Note 2. Summary of Significant Accounting
Policies, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements for a complete description of our significant accounting policies.
Recently Issued Accounting Pronouncements
Please refer to Note 2. Summary of Significant Accounting Policies, in the accompanying notes to the unaudited Condensed Consolidated Financial Statements included elsewhere in this Quarterly Report
on Form 10-Q for a description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations.
| Item 3. |
Quantitative and Qualitative Disclosures About Market Risk
|
Inflation risk
We believe inflation can and has had an impact on the underlying cost of our supplies and manufacturing components related to our business. To the extent our costs are impacted by general inflationary
pressures, we may not be able to fully offset such higher costs through price increases or manufacturing efficiencies. Our inability or failure to do so could harm our business, financial condition, results of operations or cash flows.
Interest rate risk
As of March 31, 2024, our marketable securities are comprised primarily of investments in money market funds backed by U.S. government issued securities, U.S. Treasury bills, and high-quality
corporate commercial paper. The primary objective of our investments is the preservation of capital to fulfill liquidity needs. We do not enter into investments for trading or speculative purposes. Based on the short-term nature of our holdings,
future interest rate changes are not expected to have a material impact on our marketable securities.
Foreign Currency Risk
Presently, we operate our business primarily within the United States, with limited sales outside the United States. To date, we have executed the majority of our transactions in U.S. dollars. In
the future, we anticipate expanding into Europe and other locations outside the United States. This expansion may include transacting business in currencies other than the U.S. Dollar. Despite this, we anticipate conducting limited activity
outside the U.S. Dollar in the near term, and therefore foreign currency translation risk is not expected to have a material impact on our Consolidated Financial Statements. However, the growth of our operations, scope of transactions outside the
United States, and the use of currencies other than the U.S. Dollar may grow in the future, at which point it is possible foreign currency translation will have a material effect on our operations. To date, we have not entered into any hedging
arrangements with respect to foreign currency risk. As our international operations grow, we will continue to reassess our approach to managing our risk relating to fluctuations in currency rates.
| Item 4. |
Controls and Procedures
|
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of the design and
operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act.
Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded,
processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include controls and procedures designed to ensure that information required to be disclosed in our reports filed
under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and
procedures, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of March 31, 2024.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the quarter ended March 31, 2024 that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.
| ITEM 1. |
LEGAL PROCEEDINGS.
|
From time to time, the Company is engaged in legal proceedings in the ordinary course of business. For further information on the Company’s legal proceedings, please refer to Note 15. Commitments and
Contingencies, in the notes to the Condensed Consolidated Financial Statements.
Our business, results of operations, financial condition and cash flows are subject to various risks and uncertainties including the risk factors described under the caption “Risk
Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, and the risk factor described below.
We rely on certain contract manufacturers to manufacture and supply our instruments, components of our instruments, and certain components of our consumable
offerings. If these manufacturers should fail or not perform satisfactorily, our ability to commercialize and supply our instruments and consumable offerings would be adversely affected.
We rely on certain contract manufacturers to manufacture and supply our instruments, components of our instruments, and certain components of our consumable offerings. Since most of our contracts with
these manufacturers do not commit them to carry inventory or make available any particular quantities, these manufacturers may give other customers’ needs higher priority than ours, and we may not be able to obtain adequate supplies in a timely
manner or on commercially reasonable terms. Further, if these manufacturers are unable to obtain critical components used in our instruments or supply our instruments on the timelines we require, our business and commercialization efforts would be
harmed. For example, in November 2023 we began a process of transitioning the manufacturing of our Platinum® instrument to a new provider. Transitioning this process
could take more time than anticipated and run into technical challenges, and may ultimately prove to be unsuccessful. If we are unable to begin manufacturing at this new contract manufacturer in a timely fashion, it will affect our ability to
produce Platinum® instruments which would harm our research and development efforts and commercial operations.
In the event it becomes necessary to utilize a different contract manufacturer for our products or components of our products, we would experience additional costs, delays and difficulties in doing so
as a result of identifying and entering into an agreement with a new manufacturer as well as preparing such new manufacturer to meet the logistical requirements associated with manufacturing our instruments and consumable offerings, and our
business would suffer. In addition, if our products are authorized for use by the FDA as medical devices, we will need to contract with FDA-registered device establishments that are able to comply with current Good Manufacturing Practice
requirements that are set forth in the QSR, unless explicitly exempted by regulation.
In addition, certain of the components and consumables used in our instruments and consumable offerings are sourced from a limited number, or sole source suppliers. If we were to lose such a supplier,
there can be no assurance that we will be able to identify or enter into an agreement with an alternative supplier on a timely basis on acceptable terms, if at all. An interruption in our ability to sell and deliver instruments or consumable
offerings to customers could occur if we encounter delays or difficulties in securing these components or consumables, or if the quality of the components or consumables supplied do not meet specifications, or if we cannot then obtain an acceptable
substitute. Our suppliers have also been impacted by the COVID-19 pandemic, and in the past, we have experienced supply delays for critical hardware and instrumentation as a result. If any of these events occur, our business, results of operations,
financial condition and prospects could be harmed.
| ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF
PROCEEDS.
|
Unregistered Sales of Equity Securities and Use of Proceeds
Not applicable.
Issuer Purchases of Equity Securities
Not applicable.
| ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES.
|
Not applicable.
| ITEM 4. |
MINE SAFETY DISCLOSURES.
|
Not applicable.
| ITEM 5. |
OTHER INFORMATION.
|
10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into
Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the three months ended March 31, 2024, none of
our officers or directors adopted terminated
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
|
Exhibit
Number
|
|
Exhibit Description
|
|
Filed Herewith
|
|
Incorporated by
Reference Herein from
Form or Schedule
|
|
Filing Date
|
|
SEC File/
Reg. Number
|
|
Nonemployee Director Compensation Policy
|
Form 10-K (Exhibit 10.16)
|
2/29/2024
|
001-39486
|
|||||||
|
Certification of the Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||
|
Certification of the Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||
|
|
Certification of the Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
X
|
|
|
|
|
|
|
|
|
Certification of the Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
X
|
|||||||||
|
101.INS
|
|
Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)
|
|
X
|
|
|
|
|||
|
101.SCH
|
|
Inline XBRL Taxonomy Extension Schema Document
|
|
X
|
|
|
|
|||
|
101.CAL
|
|
Inline XBRL Taxonomy Extension Calculation Linkbase Document
|
|
X
|
|
|
|
|||
|
101.DEF
|
Inline XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
||||||||
|
101.LAB
|
Inline XBRL Taxonomy Extension Label Linkbase Document
|
X
|
||||||||
|
101.PRE
|
Inline XBRL Taxonomy Extension Presentation Linkbase Document
|
X
|
||||||||
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
X
|
|
+
|
Management contract or compensatory plan or arrangement.
|
|
*
|
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the Securities and Exchange Commission and are not to be
incorporated by reference into any filing of Quantum-Si Incorporated under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of such Form 10-Q), irrespective
of any general incorporation language contained in such filing.
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
QUANTUM-SI INCORPORATED
|
|||
|
Date: May 9, 2024
|
By:
|
/s/ Jeffrey Hawkins
|
|
|
Jeffrey Hawkins
|
|||
|
President and Chief Executive Officer
|
|||
|
Date: May 9, 2024
|
By:
|
/s/ Jeffry Keyes
|
|
|
Jeffry Keyes
|
|||
|
Chief Financial Officer and Treasurer
|
|||
29